Main Street Research LLC Buys Shares of 7,100 Hims & Hers Health, Inc. (NYSE:HIMS)

Main Street Research LLC bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 7,100 shares of the company's stock, valued at approximately $210,000.

Other hedge funds also recently bought and sold shares of the company. Farallon Capital Management LLC grew its position in Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after buying an additional 8,364,000 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after buying an additional 4,145,305 shares during the last quarter. Vanguard Group Inc. grew its position in Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after buying an additional 2,020,722 shares during the last quarter. Renaissance Technologies LLC grew its position in Hims & Hers Health by 29.0% in the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock valued at $168,079,000 after buying an additional 1,562,302 shares during the last quarter. Finally, Invesco Ltd. grew its position in Hims & Hers Health by 613.9% in the 4th quarter. Invesco Ltd. now owns 1,277,026 shares of the company's stock valued at $30,878,000 after buying an additional 1,098,148 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,572 shares of the company's stock in a transaction that occurred on Monday, June 30th. The stock was sold at an average price of $50.50, for a total value of $129,886.00. Following the completion of the transaction, the insider owned 160,737 shares in the company, valued at $8,117,218.50. This represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Irene Becklund sold 8,485 shares of the company's stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total value of $506,978.75. Following the completion of the transaction, the insider directly owned 712 shares in the company, valued at approximately $42,542. The trade was a 92.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 670,250 shares of company stock worth $34,487,591. Company insiders own 13.71% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. UBS Group set a $30.00 target price on Hims & Hers Health in a report on Monday, June 23rd. Truist Financial set a $45.00 target price on Hims & Hers Health in a report on Tuesday, June 24th. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Bank of America raised their target price on Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a report on Tuesday, April 29th. Finally, Piper Sandler reissued a "neutral" rating and issued a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $39.58.

Hims & Hers Health Stock Performance

HIMS stock traded down $2.36 during trading on Friday, hitting $47.91. The stock had a trading volume of 18,925,676 shares, compared to its average volume of 23,837,558. The company's 50 day moving average price is $53.68 and its two-hundred day moving average price is $40.96. Hims & Hers Health, Inc. has a 1-year low of $13.47 and a 1-year high of $72.98. The stock has a market cap of $10.72 billion, a price-to-earnings ratio of 69.44, a price-to-earnings-growth ratio of 1.85 and a beta of 2.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The firm's revenue for the quarter was up 110.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.05 EPS. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.